Aktis Oncology, Inc. (AKTS) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 28.42 |
| Open | 27.95 |
| Day High | 28.65 |
| Day Low | 26.52 |
| 52-Week High | 34.19 |
| 52-Week Low | 14.72 |
| Volume | 487,209 |
| Average Volume | 325,822 |
| Market Cap | 1.49B |
| PE | -1.5 |
| EPS | -18.57 |
| Moving Average 50 Days | 22.37 |
| Moving Average 200 Days | 20.5 |
| Change | -0.54 |
Aktis Oncology to Present at Upcoming March Investor Conferences
GlobeNewswire Inc.
Feb 24, 2026 9:05 PM GMT
BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addre
Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate
GlobeNewswire Inc.
Feb 24, 2026 1:00 PM GMT
U.S. FDA Fast Track designation granted to AKY-11891 for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have progressed on or after prior systemic therapiesOngoing Phase 1b trial of AKY-1189 enrolling patien
Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
GlobeNewswire Inc.
Jan 13, 2026 11:30 AM GMT
BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed